Join
Live feed
·
PRReleasevia Quantisnow
Apogee Therapeutics Inc. logo

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
APGE· Apogee Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APGE (Apogee Therapeutics Inc.) and more on Quantisnow.